Keep current on the latest news from Allegro Ophthalmics

Sign up today to be notified about the initiation of clinical trials, study results and breaking company news.

Your info will never be shared with a third-party

No Thanks

Welcome to Allegro Ophthalmics

Accelerated Innovation. Needed Intervention.

With more than 100 years of combined experience in ophthalmic drug discovery, development, and manufacturing, the leadership team at Allegro Ophthalmics is establishing Integrin Peptide Therapy as the next generation pharmaceutical category for the treatment of vitreo-retinal diseases.

Allegro’s lead investigational drug Luminate® has been shown to significantly reduce the current burden of intravitreal injections and to be a viable option for patients with wet age-related macular degeneration and diabetic macular edema.

The potential to liberate patients from vision loss to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.

Allegro Vision & Mission
Our vision is to bring new therapies to market to ensure that more people retain their vision and do not suffer from blindness.


Luminate® shows promise with two new mechanisms of action for the prevention and management of vitreo-retinal diseases.